Detalles de la búsqueda
1.
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med
; 388(26): 2444-2455, 2023 Jun 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37379135
2.
Central Reading of Ulcerative Colitis Clinical Trial Videos Using Neural Networks.
Gastroenterology
; 160(3): 710-719.e2, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33098883
3.
Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 20(1): 105-115.e14, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32950748
4.
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
Br J Dermatol
; 187(6): 866-877, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35791755
5.
Systemic administration of a ß2-adrenergic receptor agonist reduces mechanical allodynia and suppresses the immune response to surgery in a rat model of persistent post-incisional hypersensitivity.
Mol Pain
; 17: 1744806921997206, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33829907
6.
Absence of VEGFR-1/Flt-1 signaling pathway in mice results in insensitivity to discogenic low back pain in an established disc injury mouse model.
J Cell Physiol
; 235(6): 5305-5317, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31875985
7.
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
N Engl J Med
; 376(7): 652-662, 2017 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-28199814
8.
Discordance of COVID-19 guidelines for patients with cancer: A systematic review.
J Surg Oncol
; 122(4): 579-593, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32668034
9.
Genetic markers associated with clinical and radiographic response in adalimumab plus methotrexate- or methotrexate-treated rheumatoid arthritis patients in OPTIMA.
Clin Exp Rheumatol
; 37(5): 783-790, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30963994
10.
Effect of Multilayering Incremental Technique on the Microleakage of High-viscosity Bulk-fill Composite Restorations in Endodontically Treated Teeth.
J Contemp Dent Pract
; 20(7): 822-827, 2019 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31597802
11.
COVID associated fungal sinusitis: An experience from a tertiary care hospital.
Clin Otolaryngol
; 48(4): 715-720, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37308457
12.
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
Ann Rheum Dis
; 76(11): 1853-1861, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28798049
13.
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.
Lancet
; 383(9914): 321-32, 2014 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-24168956
14.
Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease.
Clin Gastroenterol Hepatol
; 13(5): 940-8.e3, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25245624
15.
Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.
Ann Rheum Dis
; 73(3): 536-43, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23316080
16.
Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.
Rheumatology (Oxford)
; 53(5): 904-13, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24441150
17.
Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies.
Intest Res
; 22(2): 172-185, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38720466
18.
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials.
Inflamm Bowel Dis
; 2024 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38271613
19.
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Inflamm Bowel Dis
; 2024 Mar 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38459910
20.
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).
Ann Rheum Dis
; 72(6): 815-22, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22772328